Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
Date
2018-09
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Description
Bu çalışma, 14-15 Eylül, 2018 tarihlerinde Paris[Fransa]’da düzenlenen Conference on Molecular Analysis for Personalised Therapy (MAP) Kongresi‘nde bildiri olarak sunulmuştur.
Keywords
Oncology
Citation
Eskiler, G. G. vd. (2018). ''Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer''. Annals of Oncology, 29(Supplement 6).